COMMUNIQUÉS West-GlobeNewswire

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
22/10/2025
Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and quality of life [...]
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
22/10/2025
Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts, Oct. 22, 2025 (GLOBE [...]
ProPhase Labs Announces Study Validating BE-Smart Esophageal Cancer Test Accepted by Journal of Clinical Gastroenterology and Hepatology
22/10/2025
Study Acceptance Supports and Provides the Catalyst for Upcoming Commercial Rollout and Revenue-Generating Potential UNIONDALE, NY, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH) (“ProPhase” or the [...]
Appili Therapeutics to Attend BARDA Innovation Symposium 2025
22/10/2025
Highlights Government-Funded Pipeline and Expanding Role of Public-Private Partnerships in Biodefense Innovation HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC Pink: [...]
Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock
22/10/2025
SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein [...]
Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
22/10/2025
ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated the SURPASS global [...]
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
22/10/2025
Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera’s dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agreement includes 1) [...]
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
22/10/2025
FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficiency (AVP-D) The [...]
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
22/10/2025
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in [...]
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
22/10/2025
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., [...]
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
22/10/2025
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential [...]
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22/10/2025
REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22/10/2025
REYKJAVIK, ICELAND (OCTOBER 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its [...]
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
22/10/2025
Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection models Progressing a platform of small-molecule enzymatic activators that induce self-digestion of bacteria as novel [...]
Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium
22/10/2025
Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivator Candidates for FGFR3 and SMARCA2 programs identified [...]
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
22/10/2025
Co-led b y Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001, in-licensed by Elevara from Japan’s Teijin Pharma with good tolerability and [...]
SPINEWAY : Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP en Australie
22/10/2025
Ecully, le 22 octobre 2025 – 8h30 SPINEWAY Evolution Surgical distribuera les prothèses discales CP-ESP et LP-ESP de Spineway en Australie Spineway, spécialiste des implants innovants pour le traitement des pathologies [...]
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
22/10/2025
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 52 1 Trial showed reduction in annual cumulative steroid dose vs placebo through Week 52; [...]
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
22/10/2025
Year-to-date total sales growth of 12.1% at CER 1 , or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo®, Bylvay® and Somatuline® Further upgrade of full-year 2025 [...]

Pages